NCT01334879

High Dose Intravitreal Ranibizumab for Recalcitrant Radiation Retinopathy

High Dose (2.0mg) Intravitreal Ranibizumab for Recalcitrant Radiation Retinopathy

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: The New York Eye Cancer Center · Academic / Other
• Sex: All
• Age: 21 Years
• Healthy volunteers: Not accepted

Summary

This study investigates the use of a high dose anti-VEGF agent for the treatment of radiation retinopathy in those patients who have recalcitrant disease.

Detailed description

This study is an open-label, Phase I study of intravitreally administered ranibizumab in subjects with radiation retinopathy. This is a single center, non-randomized, active treatment study involving 10 consecutive patients. This study will evaluate the safety and tolerability of a high dose (2.0 mg) intravitreal ranibizumab and its effect on regression of radiation retinopathy and mean change in visual acuity.

Conditions

• Radiation Retinopathy

Interventions

Type	Name	Description
DRUG	ranibizumab 2.0 mg	Intravitreal ranibizumab (2.0 mg)

Timeline

• Start date: 2011-05-01
• Primary completion: 2012-11-01
• Completion: 2012-11-01
• First posted: 2011-04-13
• Last updated: 2014-10-02

Locations

1 site across 1 country: United States